EVITA Manuscript - Final Verified

Section

Bookeeping tables during data processing

ID before and after main file

Before	After
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100
101	101
102	102
103	103
104	104
105	105
106	106
AAL-01	AAL1
AAL-02	AAL2
AAL-03	AAL3
AAL-04	AAL4
AAL-05	AAL5
USC-52	USC52
USC-53	USC53
USC-54	USC54
USC-55	USC55
USC-56	USC56
USC-57	USC57
USC-59	USC59
USC-60	USC60

ID before and after VAFS file

Before	After
23-1-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S84	23
23-1-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S84	23
23-2-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S85	23
23-2-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S85	23
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83	26
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90	35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91	35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91	35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91	35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91	35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91	35
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131	1
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131	1
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131	1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132	1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132	1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132	1
3-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S33	3
3-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S33	3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34	3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34	3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34	3
7-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S121	7
7-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S121	7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122	7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122	7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122	7
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124	8
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63	10
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63	10
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63	10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64	10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64	10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64	10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64	10
11-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S35	11
11-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S36	11
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37	12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37	12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37	12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37	12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37	12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38	12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38	12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38	12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38	12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38	12
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40	13
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125	15
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125	15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126	15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126	15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126	15
16-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S41	16
16-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S41	16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42	16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42	16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42	16
18-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S127	18
18-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S127	18
18-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S128	18
18-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S128	18
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43	19
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43	19
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43	19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44	19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44	19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44	19
20-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S65	20
20-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S65	20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66	20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66	20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66	20
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67	22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68	22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68	22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68	22
27-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S45	27
27-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S46	27
28-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S1	28
28-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S1	28
28-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S2	28
28-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S2	28
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47	29
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47	29
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47	29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48	29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48	29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48	29
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
32-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S79	32
33-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S3	33
33-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S4	33
34-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S80	34
34-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S80	34
34-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S81	34
34-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S81	34
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49	36
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49	36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50	36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50	36
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115	37
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115	37
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115	37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116	37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116	37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116	37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116	37
39-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S93	39
39-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S94	39
40-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S133	40
40-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S134	40
40-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S134	40
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95	41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95	41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95	41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95	41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95	41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96	41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96	41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96	41
43-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S82	43
44-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S5	44
44-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S5	44
44-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S6	44
44-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S6	44
46-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S129	46
46-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S130	46
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7	47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7	47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7	47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7	47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8	47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8	47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8	47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8	47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8	47
48-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S83	48
48-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S83	48
49-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S97	49
49-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S98	49
50-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S99	50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100	50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100	50
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101	51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101	51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101	51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101	51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102	51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102	51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102	51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102	51
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103	64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103	64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103	64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103	64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104	64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104	64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104	64
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85	67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85	67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85	67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85	67
68-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S9	68
68-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S9	68
68-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S10	68
68-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S10	68
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12	69
72-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S51	72
72-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S52	72
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13	74
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13	74
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13	74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14	74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14	74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14	74
76-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S87	76
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16	78
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17	81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17	81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17	81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17	81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18	81
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19	83
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19	83
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19	83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20	83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20	83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20	83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20	83
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21	84
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21	84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22	84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22	84
86-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S23	86
86-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S23	86
86-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S24	86
86-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S24	86
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88	87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88	87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88	87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88	87
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25	89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25	89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25	89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25	89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26	89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26	89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26	89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26	89
94-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S27	94
94-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S28	94
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53	97
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53	97
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53	97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54	97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54	97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54	97
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29	98
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29	98
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29	98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30	98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30	98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30	98
100-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S31	100
100-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S31	100
100-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S32	100
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111	103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111	103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111	103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111	103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112	103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112	103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112	103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112	103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112	103
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119	105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119	105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119	105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55	106
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55	106
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55	106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56	106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56	106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56	106
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117	AAL1
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117	AAL1
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117	AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118	AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118	AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118	AAL1
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57	AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57	AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57	AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57	AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58	AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58	AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58	AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58	AAL2
AAL3-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S59	AAL3
AAL3-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S60	AAL3
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135	AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135	AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135	AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135	AAL4
AAL5-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S61	AAL5
AAL5-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S61	AAL5
AAL5-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S62	AAL5
AAL5-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S62	AAL5
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105	USC52
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105	USC52
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105	USC52
USC52-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S106	USC52
USC52-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S106	USC52
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
2-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S1	2
2-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S2	2
4-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S3	4
4-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S4	4
4-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S4	4
5-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S5	5
5-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S5	5
5-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S6	5
5-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S6	5
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7	6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7	6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7	6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7	6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8	6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8	6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8	6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8	6
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9	9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9	9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9	9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9	9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10	9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10	9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10	9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10	9
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14	21
24-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S15	24
24-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S15	24
24-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S16	24
24-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S16	24
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17	25
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17	25
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17	25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18	25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18	25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18	25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18	25
38-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S19	38
38-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S20	38
42-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S23	42
42-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S24	42
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25	45
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25	45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26	45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26	45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26	45
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27	62
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27	62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28	62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28	62
63-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S29	63
63-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S30	63
65-1-CD34Pos-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S31	65
65-2-CD34Pos-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S32	65
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33	66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33	66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33	66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33	66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34	66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34	66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34	66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34	66
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35	70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35	70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35	70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35	70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36	70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36	70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36	70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36	70
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37	71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37	71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37	71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37	71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38	71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38	71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38	71
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40	73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40	73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40	73
75-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S41	75
75-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S41	75
75-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S42	75
75-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S42	75
77-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S43	77
77-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S44	77
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45	79
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45	79
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46	79
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47	80
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47	80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48	80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48	80
82-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S50	82
85-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S51	85
85-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S52	85
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53	88
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53	88
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53	88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54	88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54	88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54	88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54	88
90-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S55	90
90-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S56	90
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57	91
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57	91
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57	91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58	91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58	91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58	91
92-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S59	92
92-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S59	92
92-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S60	92
92-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S60	92
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61	93
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61	93
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61	93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62	93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62	93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62	93
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63	95
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63	95
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63	95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64	95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64	95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64	95
99-1-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S67	99
99-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S68	99
102-1-PBGran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S70	102
102-5-PBGran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S71	102
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72	AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72	AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72	AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72	AAL4
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73	USC54
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73	USC54
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73	USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74	USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74	USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74	USC54
USC55-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S75	USC55
USC55-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S76	USC55
USC56-1-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S77	USC56
USC56-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S78	USC56
USC57-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S79	USC57
USC57-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S79	USC57
USC57-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S80	USC57
USC57-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S80	USC57
USC59-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S81	USC59
USC59-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S81	USC59
USC59-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S82	USC59
USC59-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S82	USC59
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125	15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126	15
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69	30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70	30
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71	31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72	31
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49	36
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49	36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50	36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50	36
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115	37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116	37
46-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S129	46
46-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S130	46
50-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S99	50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100	50
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84	67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85	67
76-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S87	76
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21	84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22	84
94-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S27	94
94-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S28	94
101-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S109	101
101-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S110	101
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113	104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114	104
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119	105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120	105
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55	106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56	106
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107	USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108	USC53
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9	9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10	9
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13	17
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17	25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18	25
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25	45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26	45
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27	62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28	62
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37	71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38	71
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39	73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40	73
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47	80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48	80
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61	93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62	93

IDs in VAFS file but not in main

x

IDs in main file but not in VAFS

x
14
96
USC60

Cumulative Clonal Growth Rates

Bookkeeping

Growth rate, 𝛼 = log (𝑉𝐴𝐹 𝑓𝑜𝑙𝑙𝑜𝑤-𝑢𝑝/𝑉𝐴𝐹 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )/𝑡𝑖𝑚𝑒 Patients 14 and 96 have no VAF info because they did not have nay VAFS, therefore their growth rate is 0

ID before and after vdate file

Before	After
1	1
1	1
1	1
2	2
2	2
2	2
2	2
2	2
3	3
3	3
3	3
3	3
3	3
4	4
4	4
4	4
4	4
4	4
5	5
5	5
5	5
5	5
5	5
6	6
6	6
6	6
6	6
6	6
7	7
7	7
7	7
7	7
7	7
8	8
8	8
8	8
8	8
8	8
9	9
9	9
9	9
9	9
9	9
10	10
10	10
10	10
10	10
10	10
11	11
11	11
11	11
11	11
11	11
12	12
12	12
13	13
13	13
13	13
13	13
13	13
14	14
14	14
14	14
14	14
14	14
15	15
15	15
15	15
15	15
15	15
16	16
16	16
16	16
16	16
16	16
17	17
18	18
18	18
18	18
18	18
18	18
19	19
19	19
19	19
19	19
19	19
20	20
20	20
20	20
20	20
20	20
21	21
22	22
22	22
22	22
22	22
22	22
23	23
23	23
23	23
24	24
24	24
24	24
24	24
24	24
25	25
25	25
25	25
25	25
25	25
26	26
26	26
26	26
26	26
26	26
27	27
27	27
27	27
27	27
27	27
28	28
28	28
28	28
28	28
28	28
29	29
29	29
29	29
29	29
29	29
30	30
30	30
30	30
30	30
30	30
31	31
31	31
31	31
31	31
31	31
32	32
33	33
33	33
33	33
34	34
34	34
34	34
34	34
35	35
35	35
35	35
35	35
35	35
36	36
36	36
36	36
36	36
36	36
37	37
37	37
37	37
37	37
37	37
38	38
38	38
38	38
38	38
38	38
39	39
39	39
39	39
39	39
39	39
40	40
40	40
40	40
40	40
40	40
41	41
41	41
41	41
41	41
41	41
42	42
42	42
42	42
42	42
42	42
43	43
44	44
44	44
45	45
45	45
45	45
45	45
45	45
46	46
46	46
46	46
46	46
46	46
47	47
47	47
47	47
47	47
47	47
48	48
49	49
49	49
49	49
49	49
49	49
50	50
50	50
50	50
50	50
50	50
51	51
51	51
51	51
51	51
51	51
62	62
62	62
62	62
62	62
62	62
63	63
63	63
63	63
63	63
63	63
64	64
64	64
64	64
64	64
64	64
65	65
65	65
65	65
66	66
66	66
66	66
66	66
66	66
67	67
67	67
67	67
67	67
67	67
68	68
68	68
68	68
68	68
68	68
69	69
69	69
69	69
69	69
69	69
70	70
70	70
70	70
70	70
70	70
71	71
71	71
71	71
71	71
71	71
72	72
72	72
72	72
72	72
72	72
73	73
73	73
73	73
73	73
73	73
74	74
74	74
74	74
75	75
75	75
75	75
75	75
75	75
76	76
77	77
77	77
77	77
77	77
77	77
78	78
78	78
78	78
78	78
79	79
79	79
79	79
79	79
79	79
80	80
80	80
80	80
80	80
80	80
81	81
81	81
82	82
83	83
83	83
83	83
83	83
83	83
84	84
84	84
84	84
84	84
84	84
85	85
85	85
85	85
85	85
85	85
86	86
86	86
86	86
86	86
86	86
87	87
88	88
88	88
88	88
88	88
88	88
89	89
89	89
89	89
89	89
89	89
90	90
90	90
90	90
90	90
90	90
91	91
91	91
91	91
91	91
91	91
92	92
92	92
92	92
92	92
92	92
93	93
93	93
93	93
93	93
93	93
94	94
94	94
94	94
94	94
94	94
95	95
95	95
95	95
95	95
95	95
96	96
96	96
96	96
96	96
96	96
97	97
97	97
97	97
97	97
97	97
98	98
98	98
98	98
98	98
98	98
99	99
99	99
99	99
99	99
99	99
100	100
100	100
100	100
100	100
100	100
101	101
101	101
101	101
101	101
101	101
102	102
102	102
102	102
102	102
102	102
103	103
103	103
104	104
104	104
104	104
104	104
104	104
105	105
105	105
105	105
105	105
105	105
106	106
106	106
106	106
106	106
106	106
AAL-01-01	AAL1
AAL-01-05	AAL1
AAL-02-01	AAL2
AAL-02-02	AAL2
AAL-03-01	AAL3
AAL-03-05	AAL3
AAL-04-01	AAL4
AAL-04-05	AAL4
AAL-05-01	AAL5
AAL-05-05	AAL5
USC-52-1	USC52
USC-52-5	USC52
USC-53-1	USC53
USC-53-5	USC53
USC-54-1	USC54
USC-54-5	USC54
USC-55-1	USC55
USC-55-5	USC55
USC-56-1	USC56
USC-56-5	USC56
USC-57-1	USC57
USC-57-5	USC57
USC-59-1	USC59
USC-59-5	USC59
USC-60-1	USC60

patients being removed from VAF analysis due to no follow-up visit

EVI2	…2	…3	…4	ID	visit
17	1	Baseline	43174	17	1
21	1	Baseline	43243	21	1
32	1	Baseline	43502	32	1
43	1	Baseline	43679	43	1
48	1	Baseline	43781	48	1
76	1	Baseline	44088	76	1
82	1	Baseline	44091	82	1
87	1	Baseline	44266	87	1
USC-60-1	1	Baseline	44550	USC60	1

Stable with no VAFS

Var1	Freq
14	1
96	1

Missing baseline and FU

ID	visit_1	AF_1	Time_1	Hugo_Symbol	cDNA_Change	visit_FU	AF_FU	Time_FU

Cumulative

All patients

Accounting: 109 patients, 9 with only a follow-up time, 3 without any VAF info, and 1 without either for a total of 11 patients excluded (8 no follow-up only, 2 no VAFS info only, 1 missing both)

	Placebo (N=51)	Vitamin C (N=49)	Overall (N=100)
GR
Mean (SD)	0.843 (3.25)	0.450 (1.98)	0.650 (2.70)
Median [Min, Max]	0.201 [-2.70, 18.4]	0.0404 [-4.69, 9.66]	0.111 [-4.69, 18.4]

emmeans and contrast

Treatment_arm emmean SE df asymp.LCL asymp.UCL Placebo 0.3057725 0.1484876 NA 0.0147422 0.5968028 Vitamin C 0.1964945 0.1514876 NA -0.1004157 0.4934048

contrast estimate SE df asymp.LCL asymp.UCL Placebo - Vitamin C 0.109278 0.2121251 NA -0.3064795 0.5250355

p-value on difference

model term	df1	df2	F.ratio	Chisq	p.value
Treatment_arm	1	Inf	0.265	0.265	0.6064424

FC from rlm

FC	asymp.LCL	asymp.UCL
1.115472	0.7360336	1.690519

Subgroups

Bookkeeping

Counts per diagnosis main file

Var1	Freq
CCUS	36
MDS	39
MDS/MPN	23
NA	2

Patients with baseline TET2, IDH1, or IDH2 mutations

	ID	Time	Hugo_Symbol
28	1	1	KRAS
29	1	1	TET2
30	1	1	TET2
59	10	1	SH2B3
60	10	1	SRSF2
61	10	1	IDH1
564	102	1	TET2
348	104	1	PTPN11
349	104	1	TET2
350	104	1	TET2
351	104	1	TET2
352	104	1	TET2
613	104	1	SRSF2
358	105	1	TET2
359	105	1	TET2
360	105	1	ZRSR2
361	105	1	PHF6
615	105	1	SRSF2
367	106	1	CBL
368	106	1	TET2
369	106	1	TET2
617	106	1	SRSF2
66	11	1	TET2
68	12	1	KRAS
69	12	1	SRSF2
70	12	1	RUNX1
71	12	1	KIT
72	12	1	TET2
78	13	1	TET2
79	13	1	TET2
80	13	1	TET2
81	13	1	TET2
82	13	1	TET2
83	13	1	ZRSR2
438	17	1	TP53
439	17	1	CEBPA
440	17	1	RUNX1
441	17	1	TET2
442	17	1	TET2
623	17	1	SRSF2
100	18	1	DNMT3A
101	18	1	TET2
104	19	1	TET2
105	19	1	TET2
106	19	1	ZRSR2
110	20	1	TET2
111	20	1	TET2
443	21	1	PTPN11
444	21	1	DNMT3A
445	21	1	U2AF1
446	21	1	TET2
447	21	1	TET2
448	21	1	TET2
449	21	1	TET2
115	22	1	DNMT3A
116	22	1	ASXL1
117	22	1	U2AF1
118	22	1	TET2
119	22	1	TET2
120	22	1	TET2
1	23	1	DNMT3A
2	23	1	IDH1
450	24	1	TET2
451	24	1	TET2
454	25	1	TET2
455	25	1	TET2
456	25	1	TET2
624	25	1	SRSF2
5	26	1	MPL
6	26	1	SH2B3
7	26	1	SH2B3
8	26	1	TET2
9	26	1	TET2
10	26	1	JAK2
126	28	1	DNMT3A
127	28	1	TET2
34	3	1	TET2
35	3	1	TET2
136	30	1	NF1
137	30	1	DNMT3A
138	30	1	RUNX1
139	30	1	RUNX1
140	30	1	TET2
141	30	1	TET2
142	30	1	BCOR
143	30	1	STAG2
590	30	1	SRSF2
151	31	1	SH2B3
152	31	1	TP53
153	31	1	TET2
154	31	1	ZRSR2
155	31	1	STAG2
592	31	1	SRSF2
163	33	1	TET2
169	36	1	TET2
170	36	1	TET2
594	36	1	NF1
595	36	1	SRSF2
185	41	1	IDH2
186	41	1	DNMT3A
187	41	1	DNMT3A
188	41	1	DNMT3A
189	41	1	TET2
463	42	1	TET2
198	46	1	IDH2
600	46	1	SRSF2
200	47	1	TET2
201	47	1	TET2
202	47	1	ZRSR2
203	47	1	ZRSR2
213	50	1	TET2
602	50	1	SRSF2
216	51	1	DNMT3A
217	51	1	TET2
218	51	1	TET2
219	51	1	TET2
422	6	1	DNMT3A
423	6	1	SF3B1
424	6	1	SF3B1
425	6	1	TET2
224	64	1	TP53
225	64	1	U2AF1
226	64	1	TET2
227	64	1	TET2
478	66	1	SF3B1
479	66	1	TET2
480	66	1	TET2
481	66	1	ZRSR2
231	67	1	PTPN11
232	67	1	RUNX1
233	67	1	TET2
234	67	1	TET2
235	67	1	TET2
604	67	1	SRSF2
244	69	1	ASXL1
245	69	1	ASXL1
246	69	1	TET2
247	69	1	TET2
248	69	1	EZH2
249	69	1	ZRSR2
250	69	1	ZRSR2
251	69	1	ZRSR2
486	70	1	PPM1D
487	70	1	TET2
488	70	1	TET2
489	70	1	TET2
494	71	1	TET2
495	71	1	TET2
496	71	1	TET2
497	71	1	TET2
630	71	1	SRSF2
501	73	1	KRAS
502	73	1	ASXL1
503	73	1	RUNX1
504	73	1	TET2
505	73	1	TET2
632	73	1	SRSF2
261	74	1	TET2
262	74	1	TET2
263	74	1	ZRSR2
509	75	1	DNMT3A
510	75	1	TET2
267	76	1	TET2
606	76	1	SRSF2
268	78	1	CBL
269	78	1	ASXL1
270	78	1	RUNX1
271	78	1	TET2
272	78	1	TET2
273	78	1	STAG2
44	8	1	CBL
45	8	1	CBL
46	8	1	CBL
47	8	1	ASXL1
48	8	1	U2AF1
49	8	1	TET2
50	8	1	TET2
51	8	1	BRAF
524	80	1	TET2
525	80	1	TET2
634	80	1	SRSF2
302	84	1	RUNX1
303	84	1	TET2
607	84	1	SRSF2
531	88	1	SF3B1
532	88	1	TET2
533	88	1	EZH2
314	89	1	ASXL1
315	89	1	TET2
316	89	1	TET2
317	89	1	ZRSR2
430	9	1	SH2B3
431	9	1	RUNX1
432	9	1	TET2
433	9	1	TET2
621	9	1	SRSF2
540	91	1	TET2
541	91	1	TET2
542	91	1	ZRSR2
546	92	1	SF3B1
547	92	1	TET2
550	93	1	IDH1
551	93	1	ZRSR2
552	93	1	ZRSR2
636	93	1	SRSF2
322	94	1	TET2
609	94	1	SRSF2
556	95	1	GNB1
557	95	1	DNMT3A
558	95	1	TET2
324	97	1	KRAS
325	97	1	ASXL1
326	97	1	TET2
330	98	1	MPL
331	98	1	TET2
332	98	1	TET2
373	AAL1	1	SRSF2
374	AAL1	1	IDH1
375	AAL1	1	RUNX1
379	AAL2	1	DNMT3A
380	AAL2	1	SF3B1
381	AAL2	1	ASXL1
382	AAL2	1	TET2
389	AAL4	1	TET2
390	AAL4	1	TET2
391	AAL4	1	ZRSR2
392	AAL4	1	ZRSR2
393	AAL5	1	SF3B1
394	AAL5	1	TET2
397	USC52	1	SF3B1
398	USC52	1	TET2
399	USC52	1	STAG2
402	USC53	1	TET2
403	USC53	1	TET2
404	USC53	1	TET2
405	USC53	1	TET2
406	USC53	1	ZRSR2
619	USC53	1	SRSF2
580	USC57	1	TET2
581	USC57	1	TET2

TET2 mutation status

Median baseline vitamin C mutation status

Baseline diagnosis

Individual mutations

Counts of each mutation

Var1	Freq
FLT3	1
GNB1	1
NRAS	1
PHF6	1
PPM1D	1
SETBP1	1
BCOR	2
BRAF	2
ETNK1	2
ETV6	2
GATA2	2
JAK2	2
KIT	2
MPL	2
CEBPA	3
EZH2	3
IDH2	3
NF1	3
PTPN11	3
IDH1	4
CBL	6
KRAS	6
SH2B3	6
STAG2	7
TP53	7
U2AF1	7
RUNX1	14
SF3B1	21
ASXL1	24
ZRSR2	26
SRSF2	27
DNMT3A	31
TET2	108

Emergence of a new mutation

emmeans and contrast

Treatment_arm emmean SE df asymp.LCL asymp.UCL Placebo -1.085708 0.3263456 Inf -1.725334 -0.4460830 Vitamin C -1.114014 0.3354149 Inf -1.771416 -0.4566132

contrast estimate SE df z.ratio p.value Placebo - Vitamin C 0.0283058 0.4734656 Inf 0.0597842 0.9523275

joint tests

model term	df1	df2	F.ratio	Chisq	p.value
Treatment_arm	1	Inf	0.004	0.004	0.9523275
time	1	Inf	0.063	0.063	0.8010501

	Placebo (N=51)	Vitamin C (N=49)	Overall (N=100)
Emergent
Mean (SD)	0.255 (0.440)	0.245 (0.434)	0.250 (0.435)
Median [Min, Max]	0 [0, 1.00]	0 [0, 1.00]	0 [0, 1.00]
time
Mean (SD)	0.920 (0.296)	1.03 (0.181)	0.972 (0.251)
Median [Min, Max]	1.02 [0.235, 1.43]	1.02 [0.249, 1.33]	1.02 [0.235, 1.43]

Progressive, stable, contracting clones

Each defined as: averaging >10% over 1 year is an expanding clones, <10% contracting clones, within +/-10% stable.

Manuscript figure

Plasma Vitamin C

Manuscript Figure

Patient plasma vitamin C level. A) Composition of all patients, placebo controls, and vitamin C treated individuals with: vitamin C deficiency, inadequate vitamin C, or adequate vitamin C at inclusion; distributions are relatively similar between the two treatment arms. B) Plasma vitamin C level at each timepoint by treatment arm; p-values were estimated using robust linear mixed-effects model with a random intercept for each individual. C) LOESS smoothed vitamin C level over time with standard error ribbons. Individuals with >200 /L vitamin C level were censored in C) to better characterize dispersion among trial participants, all individual measures are shown in panel B).

Supplemental figure, Vitamin C change over time

Supplemental figure xx. Change in vitamin C over time.

	Placebo (N=54)	Vitamin C (N=55)	Overall (N=109)
Baseline Vitamin C
Mean (SD)	43.66 (24.55)	47.64 (25.17)	45.67 (24.83)
Median (Min, Max)	43.75 (22.20, 60.39)	45.85 (29.80, 69.12)	44.18 (27.33, 63.32)
EOT Vitamin C
Mean (SD)	45.31 (31.09)	83.22 (24.40)	65.12 (33.56)
Median (Min, Max)	48.73 (20.56, 58.21)	81.90 (67.08, 99.57)	63.82 (47.69, 87.34)
Missing	12 (22.2%)	9 (16.4%)	21 (19.3%)

change in vitamin C

Treatment_arm	emmean	SE	df	z.ratio	p.value
Placebo	-0.7534369	4.882218	NA	-0.1543227	0.8773553
Vitamin C	36.8381243	4.665120	NA	7.8965003	0.0000000

Fold change in vitamin C

Treatment_arm response SE df asymp.LCL asymp.UCL Placebo 0.9257738 0.0960257 NA 0.7554647 1.134477 Vitamin C 1.9340593 0.1916894 NA 1.5925941 2.348737

contrast ratio SE df asymp.LCL asymp.UCL Placebo / Vitamin C 0.4786688 0.0686721 NA 0.3613414 0.6340922

Supplemental figure, plasma versus bone marrow vitamin C

Correlate Vitamin C in plasma and bone marrow

Spearman

Survival

Includes all samples, unadjusted. We also performed a landmark analysis and analyzed this same data with peto-peto. Both were still significant, therefore an FDR correction would not change our findings here.

Primary outcome KM (Figure 3)

Unadjusted Kaplan-Meier curves for overall survival. Estimated hazard ratio for vitamin C treated patients versus controls based on an unadjusted Cox proportional hazards regression 0.35, 95% CI 0.17, 0.71.

	Placebo (N=54)	Vitamin C (N=55)	Overall (N=109)
Follow up (Months)
Mean (sd)	30.6 (17.0)	39.3 (17.8)	35.0 (17.9)
Median [Q1, Q3]	28.1 [18.2, 41.2]	36.4 [25.8, 49.5]	33.6 [21.4, 48.3]
Event
Censored	30 (55.6%)	44 (80.0%)	74 (67.9%)
Died	24 (44.4%)	11 (20.0%)	35 (32.1%)

Hazard ratio and CI

	exp(coef)	exp(-coef)	lower .95	upper .95
Treatment_armVitamin C	0.3473816	2.878679	0.1697418	0.7109265

Cox model (No interaction)

Supplemntal figure XX. Forest plot for adjusted Cox model. Cox proportional hazards regression to estimated efficacy of vitamin C on overall survival was adjusted for patient age at inclusion, gender, hemoglobin levels at inclusion, and whether or not they had been diagnosed with CCUS.

Cox model (Age interaction)

Supplemental figure XX. Forest plot for adjusted Cox model in age interaction. Cox proportional hazards regression to estimated efficacy of vitamin C as a function of age. Age was mean centered and converted to decades to improve hazard ratio scales. Overall vitamin C was still effective, with evidence that it’s efficacy decreases with age.

Cox model (TET interaction)

	Placebo	Vitamin C
TET2Mut	32	31
TET2neg	22	24

Cox model (Hb1 interaction)

Cox model (Sex interaction)

Cox model (CCUS interaction)

Forest plot cannot be made due to diverging SE in treatment

## Call:
## coxph(formula = Surv(Days_FU_OS, FU_Death) ~ VitaminC + age_c + 
##     vitc_ccus + Male + Hb1_c + CCUS, data = df)
## 
##                       coef        exp(coef)         se(coef)      z        p
## VitaminC    -0.48013788583    0.61869807622    0.39738120115 -1.208 0.226949
## age_c        0.04289957950    1.04383306735    0.02439246075  1.759 0.078625
## vitc_ccus  -18.85453900918    0.00000000648 5424.03021304527 -0.003 0.997226
## Male         0.84285200671    2.32298270049    0.46551028687  1.811 0.070203
## Hb1_c       -0.67791720098    0.50767327337    0.18565236465 -3.652 0.000261
## CCUS         0.23284559292    1.26218657373    0.51029109759  0.456 0.648175
## 
## Likelihood ratio test=40.98  on 6 df, p=0.0000002919
## n= 109, number of events= 35

Cox model (baseline vitamin C interaction)

2-year landmark

Maybe Figure? A 2 year landmark analysis was performed to determine if there was still evidence of vitamin C efficacy after removing individuals who had events prior to 2 years. This landmark analysis ensures the effects of vitamin C had sufficient time to reach efficacy.

Removed from landmark

ID	Days_FU_OS	FU_Death	Treatment_arm
9	531	1	Vitamin C
12	403	1	Placebo
17	113	1	Vitamin C
23	360	1	Placebo
27	606	1	Vitamin C
30	621	1	Vitamin C
33	646	1	Placebo
35	683	1	Placebo
37	379	1	Placebo
42	618	1	Placebo
44	132	1	Placebo
65	235	1	Placebo
73	413	1	Placebo
78	479	1	Placebo
81	250	1	Placebo
83	578	1	Vitamin C
87	391	1	Placebo
95	701	0	Placebo
96	666	0	Vitamin C
97	658	0	Placebo
98	650	0	Vitamin C
99	650	0	Vitamin C
100	608	0	Vitamin C
101	594	0	Placebo
102	539	0	Placebo
103	152	1	Vitamin C
104	462	0	Vitamin C
105	401	0	Vitamin C
106	364	0	Placebo
AAL2	509	1	Placebo
AAL5	386	0	Placebo
USC53	695	1	Placebo
USC59	714	0	Placebo
USC60	1	0	Placebo

Per patient protocol

likelihood ratio test p-value is nearly identical to log-rank

IDs removed from main

x
1
12
17
21
23
30
32
33
35
37
43
44
48
65
72
74
76
78
81
82
87
96
103
AAL2
AAL4

LRT on treatment

#Df	LogLik	Df	Chisq	Pr(>Chisq)
1	-76.00080	NA	NA	NA
0	-77.16977	-1	2.337937	0.1262567

Subgroups (suppl)

All subgroup analyses include only the hazard ratio with 95% CI as these are exploratory.

TET1 or IDH1/2 at baseline

Supplemental Figure XX. Overall survival by TET2 or IDH1/2 mutation status. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by TET2 and IDH1/2 mutation status. Survival curves and estimates are consistent with the primary outcome.

LRT for interaction

#Df	LogLik	Df	Chisq	Pr(>Chisq)
3	-142.8280	NA	NA	NA
2	-143.5895	-1	1.523109	0.2171495

Manuscript Figure

LOF TET2

AKA TET2 hypermethylation vs WT signature

LRT for interaction

#Df	LogLik	Df	Chisq	Pr(>Chisq)
3	-107.0926	NA	NA	NA
2	-107.8713	-1	1.557548	0.2120246

Above/Below median Vitamin C

Supplemental figure XX. Overall survival by vitamin C above or below median vitamin C at inclusion. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by patients with plasma vitamin C level below the median measure at inclusion, and greater than or equal to the median. Results are consistent with the primary outcome.

LRT for interaction

#Df	LogLik	Df	Chisq	Pr(>Chisq)
3	-142.7831	NA	NA	NA
2	-142.7974	-1	0.0284974	0.8659447

Diagnostic subgroup

Supplemental figure XX. Overall survival by diagnostic subgroup at inclusion. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by diagnosis at inclusion. CCUS appears to be a subgroup that can benefit particularly well from vitamin C supplementation.

LRT for interaction

#Df	LogLik	Df	Chisq	Pr(>Chisq)
11	-134.4270	NA	NA	NA
6	-138.5647	-5	8.275447	0.1416943

Competing risk regression (progression)

For this analysis death is a competing risk of high-risk progression. We are a bit limited in sample size and events; there are only 14 progression events. Power to detect any differences in progression is quite low and we will have difficulty adjusting for any covariates here. We see corroboration with our overall survival findings that death (the dotted lines) are significantly different, however we do not have enough evidence to determine if progression also differs.

Global Methylation

Figure XX. Global methylation changes over time by treatment arm A) 5-mC/dG and B) 5-hmC/5-mC level for each patient at inclusion and end-of-therapy (EOT) and the change in these measures between inclusion and EOT. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and time point to assess if measures changed differently over time. Models also included a covariate for batch.

Methylation IDs not in Mass Spec data

x
75
79
6
5
4
26
47
23
93

Delta 5-mC and 5-hmC/5-mC

TET2

baseline vitamin C

Diagnosis

Baseline 5-mC and 5-hmC/5-mC

The raw p-values should be printing in each section

Saved p-values and FDR adjustments

outcome	subgroup	p	FDR
mC.dG	TET2	0.1991000	0.2844286
mC.dG	vitc_med	0.1066000	0.2132000
mC.dG	vitc_ccus	0.0078000	0.0390000
mC.dG	vitc_ccus	0.6186000	0.6873333
mC.dG	vitc_ccus	0.0797000	0.2092500
hmC.mC	TET2	0.0000001	0.0000009
hmC.mC	vitc_med	0.5790000	0.6873333
hmC.mC	vitc_ccus	0.7838000	0.7838000
hmC.mC	vitc_ccus	0.1405000	0.2341667
hmC.mC	vitc_ccus	0.0837000	0.2092500

TET2

baseline vitamin C

Diagnosis

5-mC/dG

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

5-hmC/dG

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

5-hmC/5-mC

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

Manuscript Figure

rlmer estimates 5mC/dG

	Estimate	Std. Error	t value	2.5%	97.5%
(Intercept)	0.0352878	0.0010852	32.5174893	0.0331609	0.0374147
Treatment_armVitamin C	0.0004736	0.0007077	0.6692364	-0.0009135	0.0018608
TimepointEOT	-0.0000521	0.0003274	-0.1590705	-0.0006938	0.0005896
Batch	0.0009001	0.0006899	1.3047354	-0.0004520	0.0022523
Treatment_armVitamin C:TimepointEOT	-0.0004371	0.0004760	-0.9183844	-0.0013700	0.0004957

Time comparisons by treatment 5mC/dG

Timepoint Treatment_arm emmean SE df asymp.LCL asymp.UCL Baseline Placebo 0.0366380 0.0005055 Inf 0.0356473 0.0376287 EOT Placebo 0.0365859 0.0005122 Inf 0.0355819 0.0375899 Baseline Vitamin C 0.0371116 0.0005036 Inf 0.0361245 0.0380987 EOT Vitamin C 0.0366224 0.0005234 Inf 0.0355966 0.0376483

contrast Treatment_arm estimate SE df z.ratio p.value Baseline - EOT Placebo 0.0000521 0.0003274 Inf 0.1590705 0.8736133 Baseline - EOT Vitamin C 0.0004892 0.0003457 Inf 1.4149172 0.1570928

anova on 5mC/dG model

	model term	df1	df2	F.ratio	Chisq	p.value
1	Treatment_arm	1	Inf	0.143	0.143	0.7057041
3	Timepoint	1	Inf	1.291	1.291	0.2558292
4	Batch	1	Inf	1.702	1.702	0.1919830
2	Treatment_arm:Timepoint	1	Inf	0.843	0.843	0.3584176

	Baseline		EOT		Overall
	Placebo (N=48)	Vitamin C (N=48)	Placebo (N=45)	Vitamin C (N=40)	Placebo (N=93)	Vitamin C (N=88)
mC.dG
Mean (SD)	0.0365 (0.00461)	0.0369 (0.00330)	0.0363 (0.00416)	0.0362 (0.00373)	0.0364 (0.00437)	0.0366 (0.00350)
Median [Min, Max]	0.0363 [0.0264, 0.0560]	0.0376 [0.0265, 0.0452]	0.0372 [0.0251, 0.0436]	0.0367 [0.0286, 0.0443]	0.0367 [0.0251, 0.0560]	0.0373 [0.0265, 0.0452]

rlmer estimates 5hmC/5mC

	Estimate	Std. Error	t value	2.5%	97.5%
(Intercept)	0.0067577	0.0008970	7.5339083	0.0049996	0.0085157
Treatment_armVitamin C	-0.0002895	0.0005735	-0.5047597	-0.0014134	0.0008345
TimepointEOT	-0.0001792	0.0001756	-1.0205230	-0.0005234	0.0001650
Batch	0.0002108	0.0005732	0.3677627	-0.0009127	0.0013343
Treatment_armVitamin C:TimepointEOT	-0.0000737	0.0002557	-0.2884575	-0.0005748	0.0004274

Time comparisons by treatment 5hmC/5mC

Timepoint Treatment_arm emmean SE df asymp.LCL asymp.UCL Baseline Placebo 0.0070739 0.0004098 Inf 0.0062707 0.0078770 EOT Placebo 0.0068947 0.0004123 Inf 0.0060865 0.0077028 Baseline Vitamin C 0.0067844 0.0004082 Inf 0.0059843 0.0075845 EOT Vitamin C 0.0065315 0.0004157 Inf 0.0057168 0.0073461

contrast Treatment_arm estimate SE df z.ratio p.value Baseline - EOT Placebo 0.0001792 0.0001756 Inf 1.020523 0.3074805 Baseline - EOT Vitamin C 0.0002529 0.0001859 Inf 1.360685 0.1736134

anova on 5hmC/5mC model

	model term	df1	df2	F.ratio	Chisq	p.value
1	Treatment_arm	1	Inf	0.337	0.337	0.5616665
3	Timepoint	1	Inf	2.855	2.855	0.0910993
4	Batch	1	Inf	0.135	0.135	0.7130502
2	Treatment_arm:Timepoint	1	Inf	0.083	0.083	0.7729965

	Baseline		EOT		Overall
	Placebo (N=48)	Vitamin C (N=48)	Placebo (N=45)	Vitamin C (N=40)	Placebo (N=93)	Vitamin C (N=88)
hmC.mC
Mean (SD)	0.00711 (0.00266)	0.00697 (0.00276)	0.00673 (0.00265)	0.00686 (0.00243)	0.00693 (0.00265)	0.00692 (0.00260)
Median [Min, Max]	0.00617 [0.00206, 0.0130]	0.00634 [0.00342, 0.0138]	0.00616 [0.00161, 0.0128]	0.00666 [0.00370, 0.0146]	0.00616 [0.00161, 0.0130]	0.00651 [0.00342, 0.0146]

Cytokines

Primary Analysis, all patients

Suppl all cytokines

Supplemental Figure XX. log2 fold-change in cytokine measures for all individuals. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and timepoint to assess if measures changed differently over time.

Significant changes over time by treatment

assay	contrast	Treatment_arm	estimate	SE	df	z.ratio	p.value	FDR	FoldChange
G-CSF	Baseline - EOT	Placebo	-0.1743696	0.0519787	Inf	-3.3546344	0.0007947	0.0037748	1.1284712
G-CSF	Baseline - EOT	Vitamin C	0.1876696	0.0526599	Inf	3.5638023	0.0003655	0.0019843	0.8780229
M-CSF	Baseline - EOT	Placebo	-0.2528030	0.0328338	Inf	-7.6994741	0.0000000	0.0000000	1.1915198
M-CSF	Baseline - EOT	Vitamin C	-0.0492938	0.0332663	Inf	-1.4817929	0.1383954	0.3578402	1.0347583
SDF-1α	Baseline - EOT	Placebo	-0.1117457	0.0299780	Inf	-3.7275946	0.0001933	0.0012243	1.0805349
SDF-1α	Baseline - EOT	Vitamin C	-0.0339439	0.0303702	Inf	-1.1176700	0.2637080	0.5203999	1.0238071
IL-8_HA	Baseline - EOT	Placebo	0.0042498	0.1529807	Inf	0.0277798	0.9778378	0.9778378	0.9970586
IL-8_HA	Baseline - EOT	Vitamin C	0.0258342	0.1550253	Inf	0.1666448	0.8676496	0.9158523	0.9822525
IP-10	Baseline - EOT	Placebo	-0.2087999	0.0477696	Inf	-4.3709833	0.0000124	0.0001567	1.1557264
IP-10	Baseline - EOT	Vitamin C	0.0196664	0.0490919	Inf	0.4006031	0.6887124	0.7697374	0.9864608
GM-CSF	Baseline - EOT	Placebo	-0.1400681	0.1612918	Inf	-0.8684141	0.3851677	0.5854549	1.1019571
GM-CSF	Baseline - EOT	Vitamin C	0.1078295	0.1630937	Inf	0.6611506	0.5085157	0.6475787	0.9279832
IL-1α	Baseline - EOT	Placebo	0.1326469	0.1872146	Inf	0.7085283	0.4786173	0.6475787	0.9121564
IL-1α	Baseline - EOT	Vitamin C	-0.3528312	0.1893061	Inf	-1.8638129	0.0623480	0.1875775	1.2770643
IL-7	Baseline - EOT	Placebo	-0.0437187	0.0496925	Inf	-0.8797848	0.3789759	0.5854549	1.0307674
IL-7	Baseline - EOT	Vitamin C	-0.0364710	0.0506757	Inf	-0.7196941	0.4717134	0.6475787	1.0256020
VEGF_cyto	Baseline - EOT	Placebo	-0.0815753	0.0440712	Inf	-1.8509883	0.0641712	0.1875775	1.0581729
VEGF_cyto	Baseline - EOT	Vitamin C	-0.0491619	0.0449321	Inf	-1.0941374	0.2738947	0.5203999	1.0346637
IFN-γ	Baseline - EOT	Placebo	-0.0916601	0.0916500	Inf	-1.0001106	0.3172570	0.5740841	1.0655956
IFN-γ	Baseline - EOT	Vitamin C	0.1292400	0.0940747	Inf	1.3738017	0.1695033	0.3578402	0.9143130
IL-10	Baseline - EOT	Placebo	-0.2665197	0.0707810	Inf	-3.7654125	0.0001663	0.0012243	1.2029025
IL-10	Baseline - EOT	Vitamin C	0.1065271	0.0726644	Inf	1.4660161	0.1426439	0.3578402	0.9288212
IL-12p70	Baseline - EOT	Placebo	0.0666808	0.0757469	Inf	0.8803108	0.3786910	0.5854549	0.9548323
IL-12p70	Baseline - EOT	Vitamin C	0.1923139	0.0776949	Inf	2.4752432	0.0133145	0.0505953	0.8752009
IL-17	Baseline - EOT	Placebo	-0.1301076	0.0924251	Inf	-1.4077087	0.1592173	0.3578402	1.0943753
IL-17	Baseline - EOT	Vitamin C	0.0604126	0.0948707	Inf	0.6367888	0.5242624	0.6475787	0.9589898
IL-1β	Baseline - EOT	Placebo	-0.0080323	0.1924598	Inf	-0.0417348	0.9667101	0.9778378	1.0055831
IL-1β	Baseline - EOT	Vitamin C	-0.1026983	0.1970958	Inf	-0.5210578	0.6023265	0.6935881	1.0737799
IL-4	Baseline - EOT	Placebo	-0.2480545	0.1781690	Inf	-1.3922428	0.1638489	0.3578402	1.1876045
IL-4	Baseline - EOT	Vitamin C	-0.0666929	0.1827328	Inf	-0.3649749	0.7151301	0.7764270	1.0473132
IL-6	Baseline - EOT	Placebo	-0.4355809	0.0822540	Inf	-5.2955589	0.0000001	0.0000023	1.3524553
IL-6	Baseline - EOT	Vitamin C	0.0532411	0.0844264	Inf	0.6306218	0.5282879	0.6475787	0.9637687
TNF-α	Baseline - EOT	Placebo	-0.1323477	0.0595905	Inf	-2.2209543	0.0263541	0.0910413	1.0960759
TNF-α	Baseline - EOT	Vitamin C	0.0537205	0.0611725	Inf	0.8781813	0.3798453	0.5854549	0.9634485
RANTES	Baseline - EOT	Placebo	0.0555723	0.0952164	Inf	0.5836425	0.5594608	0.6643597	0.9622127
RANTES	Baseline - EOT	Vitamin C	-0.3102476	0.0977680	Inf	-3.1733040	0.0015071	0.0063635	1.2399205
TGF-β1	Baseline - EOT	Placebo	-0.0286679	0.0425698	Inf	-0.6734335	0.5006716	0.6475787	1.0200698
TGF-β1	Baseline - EOT	Vitamin C	-0.1645150	0.0436554	Inf	-3.7684954	0.0001642	0.0012243	1.1207892

Cytokines that changed differently over time for Placebo versus Vitamin C

	assay	p	est	se	FDR
1	G-CSF	0.0000010	0.3620392	0.0739923	0.0000189
2	M-CSF	0.0000134	0.2035091	0.0467409	0.0001270
5	IP-10	0.0008518	0.2284663	0.0684978	0.0032369
11	IL-10	0.0002355	0.3730469	0.1014400	0.0011187
16	IL-6	0.0000337	0.4888220	0.1178709	0.0002133
18	RANTES	0.0073504	-0.3658199	0.1364725	0.0232761

Cytokine figure

Supplemental Figure XX. log2 fold-change in cytokine measures that changed significantly. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and timepoint to assess if measures changed differently over time. Larger points indicate the mean log2(fold-change) with 95% CI error bars. Scales were limited to +/-1.5 log2(fold-change) to better characterize dispersion, all data points are shown in supplemental figure XX. P-values were false discovery rate adjusted using Benjamini-Hochberg.

	assay	Treatment_arm	FoldChange	FC.CI	Median change	IQR	Q1	Q3
7	IL-6	Placebo	1.3524553	1.21, 1.51	978.7228275	4825.271944	-547.8988763	4277.373068
8		Vitamin C	0.9637687	0.86, 1.08	-305.2321957	2914.539854	-2108.8462637	805.693590
5	IL-10	Placebo	1.2029025	1.09, 1.32	48.3126753	560.975421	-64.9184297	496.056992
6		Vitamin C	0.9288212	0.84, 1.03	-48.4402901	366.301656	-225.0746532	141.227002
3	G-CSF	Placebo	1.1284712	1.05, 1.21	0.3595211	7.581336	-1.5821809	5.999155
4		Vitamin C	0.8780229	0.82, 0.94	-0.9363409	5.804647	-4.5238150	1.280832
9	M-CSF	Placebo	1.1915198	1.14, 1.25	1.9633393	3.361131	0.7072681	4.068399
10		Vitamin C	1.0347583	0.99, 1.08	0.4335928	3.483504	-1.5130604	1.970444
1	CXCL10 (IP-10)	Placebo	1.1557264	1.08, 1.23	97.4263341	380.265155	-12.0727578	368.192398
2		Vitamin C	0.9864608	0.92, 1.05	-26.4342630	342.846245	-202.3496241	140.496621
11	RANTES (CCL5)	Placebo	0.9622127	0.85, 1.1	-47.1448291	2897.441686	-1427.1604226	1470.281263
12		Vitamin C	1.2399205	1.09, 1.42	337.3523208	3489.165477	-1355.5910368	2133.574440

Volcano plots of each subroup by assay

Subgroup plots

All subgroups

95% CIs for subgroup comparisons

TET2

Showing only those with FDR < 0.1

## 
## 
## |Var1      |Var2           |Var3                        | Freq|
## |:---------|:--------------|:---------------------------|----:|
## |Placebo   |G-CSF          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |G-CSF          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |IL-10          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |IL-10          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |IL-6           |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |IL-6           |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |CXCL10 (IP-10) |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |CXCL10 (IP-10) |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |M-CSF          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |M-CSF          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |TGF-β1         |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |TGF-β1         |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |TNF-α          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |TNF-α          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |VEGF           |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |VEGF           |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |G-CSF          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |G-CSF          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |IL-10          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |IL-10          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |IL-6           |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |IL-6           |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |CXCL10 (IP-10) |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |CXCL10 (IP-10) |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |M-CSF          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |M-CSF          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |TGF-β1         |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |TGF-β1         |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |TNF-α          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |TNF-α          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |VEGF           |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |VEGF           |TET2 or IDH1/2 mutation     |   31|

Median Vitamin C

## 
## 
## |Var1      |Var2           |Var3                   | Freq|
## |:---------|:--------------|:----------------------|----:|
## |Placebo   |G-CSF          |Below median vitamin C |   28|
## |Vitamin C |G-CSF          |Below median vitamin C |   26|
## |Placebo   |IL-10          |Below median vitamin C |   28|
## |Vitamin C |IL-10          |Below median vitamin C |   26|
## |Placebo   |IL-6           |Below median vitamin C |   28|
## |Vitamin C |IL-6           |Below median vitamin C |   26|
## |Placebo   |CXCL10 (IP-10) |Below median vitamin C |   28|
## |Vitamin C |CXCL10 (IP-10) |Below median vitamin C |   26|
## |Placebo   |M-CSF          |Below median vitamin C |   28|
## |Vitamin C |M-CSF          |Below median vitamin C |   26|
## |Placebo   |RANTES (CCL5)  |Below median vitamin C |   28|
## |Vitamin C |RANTES (CCL5)  |Below median vitamin C |   26|
## |Placebo   |TGF-β1         |Below median vitamin C |   28|
## |Vitamin C |TGF-β1         |Below median vitamin C |   26|
## |Placebo   |G-CSF          |Above median vitamin C |   26|
## |Vitamin C |G-CSF          |Above median vitamin C |   28|
## |Placebo   |IL-10          |Above median vitamin C |   26|
## |Vitamin C |IL-10          |Above median vitamin C |   28|
## |Placebo   |IL-6           |Above median vitamin C |   26|
## |Vitamin C |IL-6           |Above median vitamin C |   28|
## |Placebo   |CXCL10 (IP-10) |Above median vitamin C |   26|
## |Vitamin C |CXCL10 (IP-10) |Above median vitamin C |   28|
## |Placebo   |M-CSF          |Above median vitamin C |   26|
## |Vitamin C |M-CSF          |Above median vitamin C |   28|
## |Placebo   |RANTES (CCL5)  |Above median vitamin C |   26|
## |Vitamin C |RANTES (CCL5)  |Above median vitamin C |   28|
## |Placebo   |TGF-β1         |Above median vitamin C |   26|
## |Vitamin C |TGF-β1         |Above median vitamin C |   28|

Diagnosis

## 
## 
## |Var1      |Var2           |Var3    | Freq|
## |:---------|:--------------|:-------|----:|
## |Placebo   |G-CSF          |CCUS    |   17|
## |Vitamin C |G-CSF          |CCUS    |   20|
## |Placebo   |IL-10          |CCUS    |   17|
## |Vitamin C |IL-10          |CCUS    |   20|
## |Placebo   |IL-1α          |CCUS    |   17|
## |Vitamin C |IL-1α          |CCUS    |   20|
## |Placebo   |IL-6           |CCUS    |   17|
## |Vitamin C |IL-6           |CCUS    |   20|
## |Placebo   |CXCL10 (IP-10) |CCUS    |   17|
## |Vitamin C |CXCL10 (IP-10) |CCUS    |   20|
## |Placebo   |M-CSF          |CCUS    |   17|
## |Vitamin C |M-CSF          |CCUS    |   20|
## |Placebo   |SDF-1α         |CCUS    |   17|
## |Vitamin C |SDF-1α         |CCUS    |   20|
## |Placebo   |G-CSF          |MDS     |   22|
## |Vitamin C |G-CSF          |MDS     |   18|
## |Placebo   |IL-10          |MDS     |   22|
## |Vitamin C |IL-10          |MDS     |   18|
## |Placebo   |IL-1α          |MDS     |   22|
## |Vitamin C |IL-1α          |MDS     |   18|
## |Placebo   |IL-6           |MDS     |   22|
## |Vitamin C |IL-6           |MDS     |   18|
## |Placebo   |CXCL10 (IP-10) |MDS     |   22|
## |Vitamin C |CXCL10 (IP-10) |MDS     |   18|
## |Placebo   |M-CSF          |MDS     |   22|
## |Vitamin C |M-CSF          |MDS     |   18|
## |Placebo   |SDF-1α         |MDS     |   22|
## |Vitamin C |SDF-1α         |MDS     |   18|
## |Placebo   |G-CSF          |MDS/MPN |   13|
## |Vitamin C |G-CSF          |MDS/MPN |   15|
## |Placebo   |IL-10          |MDS/MPN |   13|
## |Vitamin C |IL-10          |MDS/MPN |   15|
## |Placebo   |IL-1α          |MDS/MPN |   13|
## |Vitamin C |IL-1α          |MDS/MPN |   15|
## |Placebo   |IL-6           |MDS/MPN |   13|
## |Vitamin C |IL-6           |MDS/MPN |   15|
## |Placebo   |CXCL10 (IP-10) |MDS/MPN |   13|
## |Vitamin C |CXCL10 (IP-10) |MDS/MPN |   15|
## |Placebo   |M-CSF          |MDS/MPN |   13|
## |Vitamin C |M-CSF          |MDS/MPN |   15|
## |Placebo   |SDF-1α         |MDS/MPN |   13|
## |Vitamin C |SDF-1α         |MDS/MPN |   15|

Correlogram